224 related articles for article (PubMed ID: 33706339)
41. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial.
Ngoc NTN; Shochet T; Raghavan S; Blum J; Nga NTB; Minh NTH; Phan VQ; Winikoff B
Obstet Gynecol; 2011 Sep; 118(3):601-608. PubMed ID: 21860289
[TBL] [Abstract][Full Text] [Related]
42. Medical abortion kit dispensing practices of community pharmacies in Pokhara Metropolitan, Nepal.
Dangi NB; Subedi S; Gyawali M; Bhattarai A; Bhandari TR
PLoS One; 2021; 16(1):e0244969. PubMed ID: 33439882
[TBL] [Abstract][Full Text] [Related]
43. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
[TBL] [Abstract][Full Text] [Related]
44. Mifepristone and misoprostol for early abortion when no gestational sac is present.
Schaff EA; Fielding SL; Eisinger S; Stadalius L
Contraception; 2001 May; 63(5):251-4. PubMed ID: 11448464
[TBL] [Abstract][Full Text] [Related]
45. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion.
Schaff EA; Stadalius LS; Eisinger SH; Franks P
J Fam Pract; 1997 Apr; 44(4):353-60. PubMed ID: 9108832
[TBL] [Abstract][Full Text] [Related]
46. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion.
Dahiya K; Mann S; Nanda S
Arch Gynecol Obstet; 2011 Jul; 284(1):59-63. PubMed ID: 20652288
[TBL] [Abstract][Full Text] [Related]
47. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
[TBL] [Abstract][Full Text] [Related]
48. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion.
Kapp N; Borgatta L; Ellis SC; Stubblefield P
Contraception; 2006 May; 73(5):525-7. PubMed ID: 16627039
[TBL] [Abstract][Full Text] [Related]
49. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
50. Medication Abortion Safety and Effectiveness With Misoprostol Alone.
Jayaweera R; Egwuatu I; Nmezi S; Kristianingrum IA; Zurbriggen R; Grosso B; Bercu C; Gerdts C; Moseson H
JAMA Netw Open; 2023 Oct; 6(10):e2340042. PubMed ID: 37889485
[TBL] [Abstract][Full Text] [Related]
51. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
52. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
Bracken H; Ngoc NT; Schaff E; Coyaji K; Ambardekar S; Westheimer E; Winikoff B
Obstet Gynecol; 2007 Apr; 109(4):895-901. PubMed ID: 17400851
[TBL] [Abstract][Full Text] [Related]
53. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial.
Grimes DA; Smith MS; Witham AD
BJOG; 2004 Feb; 111(2):148-53. PubMed ID: 14723752
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial.
Abbas DF; Blum J; Ngoc NT; Nga NT; Chi HT; Martin R; Winikoff B
Obstet Gynecol; 2016 Nov; 128(5):1077-1083. PubMed ID: 27741182
[TBL] [Abstract][Full Text] [Related]
55. Availability and prescription of misoprostol for medical abortion in community pharmacies and associated factors in Accra, Ghana.
Ganle JK; Busia NT; Maya E
Int J Gynaecol Obstet; 2019 Feb; 144(2):167-173. PubMed ID: 30451283
[TBL] [Abstract][Full Text] [Related]
56. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
[TBL] [Abstract][Full Text] [Related]
57. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Guengant JP; Bangou J; Elul B; Ellertson C
Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
[TBL] [Abstract][Full Text] [Related]
58. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
[TBL] [Abstract][Full Text] [Related]
59. Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore.
Tan YL; Singh K; Tan KH; Gosavi A; Koh D; Abbas D; Winikoff B
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():144-147. PubMed ID: 30179732
[TBL] [Abstract][Full Text] [Related]
60. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Baird DT; Sukcharoen N; Thong KJ
Hum Reprod; 1995 Jun; 10(6):1521-7. PubMed ID: 7593528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
